Amylyx Pharmaceuticals reported a Phase 3 success for avexitide (a GLP-1 receptor antagonist) in patients with post-bariatric hypoglycemia, positioning the company to seek regulatory approval for a first-in-class option. In the pivotal trial, avexitide cut the rate of serious low-blood-sugar events by 55% versus placebo. Amylyx said the study was statistically powered for a 35% improvement threshold and that the observed effect exceeded expectations. The company’s co-CEO Justin Klee called the result “exciting,” emphasizing the clinical relevance of reducing medical emergencies such as seizures or loss of consciousness. Industry focus now shifts to the next regulatory steps and whether the trial effect holds across subgroups, as Amylyx continues rebuilding its GLP-1 antagonist strategy after a prior period of uncertainty.